The story of the European Randomized Study of Screening for Prostate Cancer

Schröder, Fritz H.; Denis, L.; Roobol, Monique J.

doi:10.1111/j.1464-410x.2003.04389.x

Cited by 113 publications

(58 citation statements)

References 80 publications

(81 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…To promote the comparability of needle biopsy reporting between the individual ERSPC centers, a Pathology Committee was established. 5 All pathology laboratories participating in the ERSPC agreed to employ the Gleason score system as a standard. Training sessions so as to reduce interobserver variation in Gleason grading were organized for the reference pathologists of the participating pathology laboratories at intervals of~2 years.…”

Section: Retrieval Of Gleason Scoresmentioning

confidence: 99%

“…The European Randomized Screening Study for Prostate Cancer (ERSPC), a multiinstitutional consortium of 8 screening centers in different European countries, attempts to provide an answer to the above issues. 5 Optimization of the protocols used for early detection of prostate cancer is currently under scrutiny. This may include the relevance of digital rectal examination and transrectal ultrasound imaging, testing of variants of PSA in the serum, e.g.…”

mentioning

confidence: 99%

See 1 more Smart Citation

Detection rates of high‐grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer

Kwast

Ciatto

Martikainen

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

Screening for prostate cancer using prostate-specific antigen (PSA) tests has led to a stage and grade shift as compared to the pre-PSA era. Effectiveness of screening for prostate cancer should be manifested by a reduction in detection rate of aggressive cancers during subsequent screening. In 6 centers of the European Randomized Screening study for Prostate Cancer, a total of 58,710 men were tested for prostate cancer. Screening centers differed with regard to age-range, screening interval and biopsy indications. During the 2nd visit, the proportion of Gleason score 6 cancers increased from 62.5 to 75%, mainly at the expense of Gleason score 7 cancers. High-grade (Gleason score 8-10) cancer detection rates varied per screening center during the 1st visit from 5.1 to 41.1, and during the 2nd visit from 6.4 to 29.3/10,000 men. The overall detection rate of high-grade cancers showed a reduction during the 2nd visit from 26 to 12/10,000 men, an effect mainly attributable to the screening center with the highest cancer detection rate (i.e. 507/10,000 men). Variations in detection rates among screening centers related among others to biopsy compliance and age range. ' 2005 Wiley-Liss, Inc.

show abstract

Section: Retrieval Of Gleason Scoresmentioning

confidence: 99%

mentioning

confidence: 99%

Detection rates of high‐grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer

Kwast

Ciatto

Martikainen

et al. 2006

Intl Journal of Cancer

View full text Add to dashboard Cite

show abstract

“…The 'Prostate Cancer Research International: Active Surveillance (PRIAS) study [12] is an international prospective observational study originating from the European Randomized Study of Screening for Prostate Cancer (ERSPC) [13]. PRIAS offers a protocol for the inclusion and follow-up of men, which is applied by a webbased instrument [14].…”

Section: Introductionmentioning

confidence: 99%

Short‐term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study

et al. 2010

View full text Add to dashboard Cite

a Gleason score of ≤ 3 + 3 = 6, and one or two positive biopsy cores, were analysed. The follow-up protocol consisted of frequent PSA measurements, digital rectal examinations, and standard repeat biopsies (the first after 1 year). The primary outcome is survival free of active therapy; the secondary endpoints are reasons for stopping AS, findings in 1-year repeat biopsies, and outcomes after radical prostatectomy (RP). RESULTSPatients were included between December 2006 and July 2008. The median (25-75th percentile) follow-up after diagnosis was 1.02 (0.6-1.5) years. The 2-year survival rate free from active therapy was 73%. Of the 82 men who changed to active therapy during the follow-up, 68 (83%) did so based on the protocol. Of the 261 repeat biopsies available for analysis, 90 (34%) showed no cancer, while 57 (22%) showed a Gleason score of > 6 or more than two positive biopsy cores. There was a relatively unfavourable PSA doubling time of 0-10 years in 53% (102/194) and 62% (33/53) of men with favourable and unfavourable re-biopsy results, respectively. After RP, four of 24 (17%) men had T3 disease and 12 (50%) had a Gleason score of > 6. CONCLUSIONAS seems feasible, but mortality outcomes are unknown. A strict follow-up protocol including standard 1-year repeat biopsies resulted in a quarter of men stopping AS after 2 years.

show abstract

“…The ERSPC was initiated in the early 1990s to study the effect of screening on prostate cancer specific mortality [8]. Between December 1993 and December 1999, in the section Rotterdam, 42,376 men aged 55-74 years were randomized after providing written consent.…”

Section: Methodsmentioning

confidence: 99%

825 Complications of initial prostate biopsy in a European randomized screening trial

Heuvel¹,

Loeb²,

Zhu³

et al. 2012

European Urology Supplements

View full text Add to dashboard Cite

The story of the European Randomized Study of Screening for Prostate Cancer

Cited by 113 publications

References 80 publications

Detection rates of high‐grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer

Detection rates of high‐grade prostate cancer during subsequent screening visits. Results of the European Randomized Screening Study for Prostate Cancer

Short‐term outcomes of the prospective multicentre ‘Prostate Cancer Research International: Active Surveillance’ study

825 Complications of initial prostate biopsy in a European randomized screening trial

Contact Info

Product

Resources

About